NRx Pharmaceuticals, Inc. (NASDAQ:NRXPW) Short Interest Update

NRx Pharmaceuticals, Inc. (NASDAQ:NRXPW) was the recipient of a significant decline in short interest during the month of February. As of February 27th, there was short interest totaling 1,650 shares, a decline of 66.2% from the February 12th total of 4,878 shares. Based on an average daily trading volume, of 15,596 shares, the days-to-cover ratio is currently 0.1 days. Based on an average daily trading volume, of 15,596 shares, the days-to-cover ratio is currently 0.1 days.

NRx Pharmaceuticals Trading Down 29.0%

NRXPW stock opened at $0.01 on Wednesday. NRx Pharmaceuticals has a 1-year low of $0.01 and a 1-year high of $0.18. The firm has a fifty day moving average price of $0.05 and a two-hundred day moving average price of $0.08.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel therapies for neuropsychiatric and neurodegenerative disorders. The company’s research pipeline includes small‐molecule candidates designed to address underlying pathophysiological mechanisms implicated in conditions such as Rett syndrome, Alzheimer’s disease and Long COVID. Leveraging a proprietary formulation and delivery approach, NRx seeks to advance compounds that have demonstrated safety in prior studies toward new indications with significant unmet medical need.

Among its lead programs, NRx is developing NP-120 (sarizotan) for the treatment of Rett syndrome, a rare genetic disorder that impacts brain development in young girls.